PurMinds believes psychedelics hold promise for neurological conditions
Interest in psychedelics has ratched up in recent years and a growing number of drug companies are beginning to explore their potential to treat everything from depression to neurodegeneration.
“It is a really really exciting time,” said Aron Buchman, chief strategy officer, PurMinds BioPharma, which is exploring psychedelics’ potential to treat neurological diseases.
American author Michael Pollan recently surmised in an interview with Independent that the psychedelics industry was in a “gold rush” phase. “Whether it’s going to work is another question. I think it’s going to be very challenging to fit into the system,” Pollan added.
Headquartered in North York, Ontario, PurMinds is based in a country that is warming up to the therapeutic potential of psychedelics. The Canadian government has granted a number of patients a federal dispensation covering the therapeutic use of p…